AQR Capital Management LLC Sells 4,709 Shares of Savara Inc (NASDAQ:SVRA)

AQR Capital Management LLC decreased its holdings in shares of Savara Inc (NASDAQ:SVRA) by 22.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,483 shares of the company’s stock after selling 4,709 shares during the period. AQR Capital Management LLC’s holdings in Savara were worth $66,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in SVRA. Bain Capital Life Sciences Investors LLC increased its position in shares of Savara by 2.3% during the first quarter. Bain Capital Life Sciences Investors LLC now owns 14,565,457 shares of the company’s stock valued at $72,536,000 after acquiring an additional 332,706 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Savara by 0.3% during the 1st quarter. Jennison Associates LLC now owns 8,841,971 shares of the company’s stock worth $44,033,000 after acquiring an additional 26,613 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Savara by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after acquiring an additional 148,673 shares during the last quarter. Farallon Capital Management LLC boosted its stake in shares of Savara by 90.5% during the 2nd quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company’s stock worth $18,377,000 after acquiring an additional 2,165,701 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Savara by 41.1% during the 1st quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock worth $12,754,000 after acquiring an additional 746,407 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Price Performance

SVRA stock opened at $3.76 on Friday. Savara Inc has a 12 month low of $3.12 and a 12 month high of $5.70. The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26. The company has a 50-day moving average price of $4.18 and a 200 day moving average price of $4.36. The stock has a market cap of $519.59 million, a PE ratio of -10.16 and a beta of 0.96.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). Equities research analysts anticipate that Savara Inc will post -0.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Oppenheimer lifted their target price on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research note on Wednesday, June 26th. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research note on Tuesday, October 1st. Guggenheim lifted their target price on shares of Savara from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Savara in a report on Tuesday, October 8th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $11.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.